TEVA PHARMACEUTICAL FINANCE NETHERLANDS IIIBV Credit Rating

Usuarios Registrados

Registro para acceso total permitido. Su contraseña es sensible a mayúsculas y minúsculas.

Nombre de Usuario:

Contraseña:

Ingresar automáticamente en mi próxima visita

Iniciar sesión

¿Olvidó su Nombre de Usuario o Contraseña?

¿No se ha registrado?

Regístrese ahora para tener acceso GRATUITO a:

Calificaciones de Emisor.

Calificaciones de más de 170,000 instrumentos de corporativos, gobiernos y finanzas estructuradas.

Calendario de Eventos.

Información de cursos de capacitación, seminarios y teleconferencias.

Listas de Calificaciones en Observación.

Listas de emisores en revisión para cambios de calificación.

Metodologías de Calificación.

Marcos descriptivos del sustento de las calificaciones de Moody's.

Resultados 1 - 24 de 24

Página 1 de 1 Next

Filtrar por:

Fecha	Tipo de Informe	Title	Source
17 Dec 2023	Rating Action	Moody's affirms Teva's Ba2 ratings; outlook stable	Moody's Investors Service
27 Jul 2023	Announcement of Periodic Review	Moody's announces completion of a periodic review for a group of Pharmaceutical issuers	Moody's Investors Service
28 Feb 2023	Rating Action	Moody's assigns Ba2 rating to Teva's new senior notes	Moody's Investors Service
27 Feb 2023	Covenant Quality Assessment	Teva Pharma Finance Netherlands II BV: Covenant Quality Post-Sale Snapshot: €_bn/$_bn (equivalent of $2,060m) Sustainability-Linked Senior Notes due 2029/2031	Moody's Investors Service
04 Oct 2022	Announcement of Periodic Review	Moody's announces completion of a periodic review for a group of Pharmaceutical issuers	Moody's Investors Service
15 Dec 2021	Rating Action	Moody's affirms Teva's Ba2 ratings; outlook revised to stable	Moody's Investors Service
15 Dec 2021	Covenant Quality Assessment	Teva Pharma Finance Netherlands II / BV Teva Pharma Finance Netherlands III B.V.: Covenant Quality Post-Sale Snapshot: $5.0bn (equivalent) Sustainability-Linked Senior Notes due 2027/2029/2030	Moody's Investors Service
08 Nov 2021	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Teva Pharmaceutical Industries Ltd	Moody's Investors Service
27 Oct 2021	Rating Action	Moody's rates Teva's new unsecured notes offering Ba2	Moody's Investors Service
15 Dec 2020	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Teva Pharmaceutical Industries Ltd	Moody's Investors Service
07 Apr 2020	Rating Action	Moody's affirms Teva's Ba2 CFR; upgrades liquidity rating to SGL-2	Moody's Investors Service
14 Jan 2020	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Teva Pharmaceutical Industries Ltd	Moody's Investors Service
27 Nov 2019	Covenant Quality Assessment	Teva Pharmaceutical Finance Netherlands II BV: Covenant Quality Post-Sale Snapshot: €1.0bn 6.0% Senior Notes due 2025/$1.0bn 7.125% Senior Notes 2025	Moody's Investors Service
14 Nov 2019	Rating Action	Moody's rates Teva's new unsecured notes offering Ba2	Moody's Investors Service
14 Aug 2019	Rating Action	Moody's affirms Teva's Ba2 CFR; outlook revised to negative	Moody's Investors Service
15 Feb 2019	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Teva Pharmaceutical Industries Ltd	Moody's Investors Service
20 Mar 2018	Covenant Quality Assessment	Teva Pharma Finance Netherlands III BV: Covenant Quality Post-Sale Snapshot: $1.25bn 6.00% Senior Notes due 2024/$1.25bn 6.75% Senior Notes due 2028	Moody's Investors Service
28 Feb 2018	Rating Action	Moody's rates Teva's new notes offering Ba2	Moody's Investors Service
12 Jan 2018	Rating Action	Moody's downgrades Teva to Ba2; outlook stable	Moody's Investors Service
14 Dec 2017	Rating Action	Moody's places Teva's Baa3 ratings on review for downgrade	Moody's Investors Service
03 Aug 2017	Rating Action	Moody's downgrades Teva's ratings to Baa3 from Baa2; outlook negative	Moody's Investors Service
31 Jan 2017	Rating Action	Moody's Affirms Teva's Baa2 rating; outlook changed to negative	Moody's Investors Service
25 Aug 2016	Announcement	Moody's: Teva's Loss of Two Copaxone Patents is Credit Negative	Moody's Investors Service
18 Jul 2016	Rating Action	Moody's assigns Baa2 stable to Teva's bond offering	Moody's Investors Service

Resultados 1 - 24 de 24

Página 1 de 1 Next

Informes & Calificaciones

Productos & Soluciones

Noticias & Eventos

Usuarios Registrados

¿No se ha registrado?

Moody's Integrity Hotline

Via the Internet:

By telephone from the United States:

By telephone from outside the United States: